Furthermore, AstraZeneca’s involvement lends credibility to Cellectis’s technology platform, potentially attracting additional partners and investors. This analysis is based on information ...

Furthermore, AstraZeneca’s involvement lends credibility to Cellectis’s technology platform, potentially attracting additional partners and investors. This analysis is based on information available ...

According to InvestingPro analysis, five analysts have revised their earnings ... Relay faces challenges from established players like AstraZeneca (NASDAQ:AZN)’s Capivasertib and emerging competitors ...

The company now projects revenues between $725-750 million for the year, up from its original guidance of over $600 million, though InvestingPro analysis indicates the ... Eplontersen (Wainua): In ...

According to Benzinga Pro, AstraZeneca's peer group average for short interest as a percentage of float is 4.04%, which means ...

AstraZeneca (AZN) stock in focus as its antibody drug Imfinzi gains EU panel support for treating muscle-invasive bladder ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

According to InvestingPro analysis, the stock is currently trading above its Fair Value, with technical indicators suggesting overbought conditions. Want deeper insights? InvestingPro offers 14 ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...